Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Blood (2024) 144 (Supplement 1): 584.

https://doi.org/10.1182/blood-2024-194593

Published: 2024

Journal Articles

Preemptive Therapy with Venetoclax for High-Risk Stage a CLL Patients: First Analysis of Prevene, a Phase II Trial of the Filo Group

Blood (2024) 144 (Supplement 1): 3256.

https://doi.org/10.1182/blood-2024-203081

Published: 2024

Journal Articles

Involvement of the JAK-STAT Pathway in the Molecular Landscape of Fusion-Free Myeloid Neoplasms with Eosinophilia

Blood (2023) 142 (Supplement 1): 78.

https://doi.org/10.1182/blood-2023-181250

Published: 2023

Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Blood (2023) 142 (Supplement 1): 3268.

https://doi.org/10.1182/blood-2023-173341

Published: 2023

Journal Articles

Characteristics and Outcomes of Adult Patients with T Prolymphocytic Leukemia: A Real World Study of the French Innovative Leukemia Group (FILO)

Blood (2022) 140 (Supplement 1): 1485–1487.

https://doi.org/10.1182/blood-2022-157399

Published: 2022

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Blood (2022) 140 (Supplement 1): 7007–7009.

https://doi.org/10.1182/blood-2022-159678

Published: 2022

Journal Articles

Long-Term Follow-up of Bendamustine Plus Rituximab Regimen in 69 Treatment Naïve (TN) Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Kamel Laribi, Stéphanie Poulain, Lise Willems, Fatiha Merabet, Charles Herbaux, Damien Roos Weil, Alix Baugier de Materre, Xavier Roussel, Sabine Tricot, Jehan Dupuis, Ronan Le Calloch, Benoit Bareau, Marie C Béné, Veronique Leblond

Blood (2022) 140 (Supplement 1): 3627–3628.

https://doi.org/10.1182/blood-2022-157394

Published: 2022

Journal Articles

High Frequency of CNS Involvement in Transformed Waldenström Macroglobulinemia

Blood (2021) 138 (Supplement 1): 2526.

https://doi.org/10.1182/blood-2021-145440

Published: 2021

Journal Articles

Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL

Thomas Chatzikonstantinou, Lydia Scarfo, Christos Demosthenous, Jana Kotaskova, Gloria Iacoboni, Evangelia Minga, Dimitra Chammou, Georgios Karakatsoulis, Elisa Albi, Miguel Alcoceba, Shaimaa El-Ashwah, Francesca Bacchiarri, Mehreen Ali Khan, Thérèse Aurran, Anne Calleja, Ramona Cassin, Sofia Chatzileontiadou, Amy Christian, Rainer Claus, Rosa Collado, Marcos Daniel De Deus Santos, Zadie Davis, Maria Dimou, David Donaldson, Gimena Dos Santos, Barbara Dreta, Maria Efstathopoulou, Alicia Enrico, Alberto Fresa, Sara Galimberti, Rocío García-Serra, Isabel González-Gascón Y Marín, Alessandro Gozzetti, Valerio Guarente, Sean Harrop, Eleftheria Hatzimichael, Yair Herishanu, Luca Inchiappa, Michalis Iskas, Ozren Jaksic, Susanne R. Janssen, Elzbieta Kalicinska, Volkan Karakus, Arnon P. Kater, Bonnie Kho, Iliana Konstantinou, Thomas Longval, Maya Koren-Michowitz, Ioannis Kotsianidis, Robert J. Kreitman, Uttam Kumar Nath, Jorge Labrador, Deepesh Lad, Kamel Laribi, Ilana Levy, Alberto Lopez-Garcia, Juan Marquet Palomanes, Stanislava Maslejova, Carlota Mayor-Bastida, Fatiha Merabet, Biljana Mihaljevic, Ivana Milosevic, Fatima Miras, Riccardo Moia, Marta Morawska, Almudena Navarro-Bailón, David Oscier, Jacopo Olivieri, Tomáš Papajík, Maria Papaioannou, Cheyenne Pierie, Anna Puiggros, Gianluigi Reda, Gian Matteo Rigolin, Rosa Ruchlemer, Luana Schiattone, Omur Gokmen Sevindik, Yandong Shen, Martin Šimkovič, Svetlana Smirnova, Dina Sameh Soliman, Martin Špaček, Annett Schiwitza, Tamar Tadmor, Liat Tourjeman, Eric Tse, Andrea Visentin, Kristina Tomic, Michel Van Gelder, Theodoros P. Vassilakopoulos, Candida Vitale, George Vrachiolias, Vojin Vukovic, Zhenshu Xu, Lucrecia Yáñez, Munci Yagci, Mohamed A Yassin, Jana Zuchnicka, Maria K. Angelopoulou, Darko Antic, Bella V. Biderman, Mark Catherwood, Marta Coscia, Antonio Cuneo, Fatih Demirkan, Blanca Espinet, Gianluca Gaidano, Romain Guièze, Olga Kalashnikova, Luca Laurenti, Stephen Mulligan, Roberta Murru, Eugene A. Nikitin, Panayiotis Panayiotidis, Gerasimos Pangalis, Irina Panovska, Viola Maria Popov, Šárka Pospíšilová, Lukas Smolej, Paolo Sportoletti, Niki Stavroyianni, Constantine S. Tam, Livio Trentin, Marek Trněný, Francesc Bosch Albareda, Michael Doubek, Anastasia Chatzidimitriou, Paolo Ghia, Kostas Stamatopoulos

Blood (2021) 138 (Supplement 1): 2635.

https://doi.org/10.1182/blood-2021-148738

Published: 2021

Journal Articles

Safety and Efficacy of Venetoclax-Based Treatment in Elderly CLL Patients: A Retrospective Study from the Filo Group

Blood (2021) 138 (Supplement 1): 3747.

https://doi.org/10.1182/blood-2021-149640

Published: 2021

Journal Articles

Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients

Blood (2021) 138 (Supplement 1): 637.

https://doi.org/10.1182/blood-2021-152515

Published: 2021

Journal Articles

A Third Anti-Sars-Cov2 mRNA Dose Does Not Overcome the Pejorative Impact of Anti-CD20 Therapy and/or Low Immunoglobulin Level in CLL/Lymphoma Patients

Maureen Chbat, Milena Kohn, Fatiha Merabet, Anne-Laure Roupie, Naelle Lombion, Amina Guemriche, Stéphanie Marque-Juillet, Victoria Raggueneau, Jennifer Osman, Marc Spentchian, Marc Delord, Sophie Rigaudeau, Caroline Besson

Blood (2021) 138 (Supplement 1): 3751.

https://doi.org/10.1182/blood-2021-150298

Published: 2021

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Blood (2021) 138 (Supplement 1): 641.

https://doi.org/10.1182/blood-2021-145624

Published: 2021

Journal Articles

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Blood (2021) 137 (25): 3495–3506.

https://doi.org/10.1182/blood.2020007303

Published: 2021

Includes: Supplemental data

Journal Articles

Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19

Blood (2020) 136 (20): 2290–2295.

https://doi.org/10.1182/blood.2020008423

Published: 2020

Includes: Supplemental data

Journal Articles

Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-139210

Published: 2020

Journal Articles

Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax

Blood (2019) 134 (Supplement_1): 807.

https://doi.org/10.1182/blood-2019-126773

Published: 2019

Journal Articles

Kinase Inhibitors (ibrutinib or idelalisib) in the Management of Chronic Lymphocytic Leukemia-Associated Autoimmune Cytopenia: A Retrospective Study of the French Innovative Leukemia Organization (FILO)

Blood (2018) 132 (Supplement 1): 3152.

https://doi.org/10.1182/blood-2018-99-112654

Published: 2018

Journal Articles

The Bendamustine Plus Rituximab Regimen Is Active and Safe in Previously Untreated Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Kamel Laribi, Stéphanie Poulain, MD, Lise Willems, MD, Fatiha Merabet, Charles Herbaux, Damien Roos-Weil, Alix Baugier de Materre, Xavier Roussel, Sabine Tricot, Jehan Dupuis, MD, Ronan Le Calloch, Benoit Bareau, Marie C Bene, PharmD,DPhil, Veronique Leblond

Blood (2017) 130 (Supplement 1): 4046.

https://doi.org/10.1182/blood.V130.Suppl_1.4046.4046

Published: 2017

Journal Articles

Retrospective Analysis of 56 Cases of Transformed Waldenström Macroglobulinemia. a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Eric Durot, MD, Cecile Tomowiak, MD, Anne-Sophie Michallet, MD, Jehan Dupuis, MD, Stephane Lepretre, Elise Toussaint, MD, Sophie Godet, Fatiha Merabet, Eric W Van Den Neste, MD PhD, Sarah Ivanoff, Jean-Marc Zini, MD PhD, Caroline Régny, Aurore Perrot, MD, Lukshe Kanagaratnam, Pierre Morel, MD, Veronique Leblond, Alain Delmer, MD PhD

Blood (2016) 128 (22): 2982.

https://doi.org/10.1182/blood.V128.22.2982.2982

Published: 2016

NARROW

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Preemptive Therapy with Venetoclax for High-Risk Stage a CLL Patients: First Analysis of Prevene, a Phase II Trial of the Filo Group

Involvement of the JAK-STAT Pathway in the Molecular Landscape of Fusion-Free Myeloid Neoplasms with Eosinophilia

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Characteristics and Outcomes of Adult Patients with T Prolymphocytic Leukemia: A Real World Study of the French Innovative Leukemia Group (FILO)

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Long-Term Follow-up of Bendamustine Plus Rituximab Regimen in 69 Treatment Naïve (TN) Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

High Frequency of CNS Involvement in Transformed Waldenström Macroglobulinemia

Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL

Safety and Efficacy of Venetoclax-Based Treatment in Elderly CLL Patients: A Retrospective Study from the Filo Group

Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients

A Third Anti-Sars-Cov2 mRNA Dose Does Not Overcome the Pejorative Impact of Anti-CD20 Therapy and/or Low Immunoglobulin Level in CLL/Lymphoma Patients

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19

Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement

Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax

Kinase Inhibitors (ibrutinib or idelalisib) in the Management of Chronic Lymphocytic Leukemia-Associated Autoimmune Cytopenia: A Retrospective Study of the French Innovative Leukemia Organization (FILO)

The Bendamustine Plus Rituximab Regimen Is Active and Safe in Previously Untreated Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Retrospective Analysis of 56 Cases of Transformed Waldenström Macroglobulinemia. a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only